Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 20, 2011, Pages 8224-8227

  Al Abed, Yousef ^a   Metz, Christine N ^a   Cheng, Kai Fan ^a   Aljabari, Bayan ^a   VanPatten, Sonya ^a   Blau, Steven ^b   Lee, Hans ^b   Ochani, Mahendar ^a   Pavlov, Valentin A ^a   Coleman, Thomas ^a   Meurice, Nathalie ^c   Tracey, Kevin J ^a   Miller, Edmund J ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; THYROXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE ACTION; HUMAN; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; SEPSIS; STRUCTURE ANALYSIS; THYROXINE BLOOD LEVEL;

ANIMALS; BINDING SITES; HUMANS; INFLAMMATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, KNOCKOUT; SEPSIS; SURVIVAL RATE; THYROID HORMONES; THYROXINE;

MUS; RODENTIA;

EID: 79957742886     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1017624108     Document Type: Article

References (33)

1. Plikat K, et al. (2007) Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism 56:239-244. (Pubitemid 46074071)
2. Bello G, et al. (2009) Nonthyroidal illness syndrome and prolonged mechanical ventilation in patients admitted to the ICU. Chest 135:1448-1454.
3. Mebis L, van den Berghe G (2009) The hypothalamus-pituitary-thyroid axis in critical illness. Neth J Med 67:332-340.
4. Umpierrez GE (2002) Euthyroid sick syndrome. South Med J 95:506-513.
5. Bernhagen J, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759. (Pubitemid 23339882)
6. Calandra T, et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170. (Pubitemid 30082360)
7. Beishuizen A, Thijs LG, Haanen C, Vermes I (2001) Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 86:2811-2816. (Pubitemid 32545744)
8. Bozza FA, et al. (2004) Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22:309-313. (Pubitemid 39480698)
9. Gando S, et al. (2001) Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med 27:1187-1193. (Pubitemid 32710206)
10. Takahashi K, et al. (2009) Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir Res 10:33.
11. Sakuragi T, et al. (2007) Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression. Surg Infect (Larchmt) 8:29-40. (Pubitemid 46598293)
12. Donnelly SC, et al. (1997) Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3:320-323. (Pubitemid 27112930)
13. Chagnon F, Metz CN, Bucala R, Lesur O (2005) Endotoxin-induced myocardial dysfunction: Effects of macrophage migration inhibitory factor neutralization. Circ Res 96:1095-1102. (Pubitemid 40791382)
14. Garner LB, et al. (2003) Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 285:H2500-2509.
15. Al-Abed Y, et al. (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 280:36541-36544. (Pubitemid 41587728)
16. Dabideen DR, et al. (2007) Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. J Med Chem 50:1993-1997. (Pubitemid 46626609)
17. Leng L, et al. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467-1476. (Pubitemid 36686708)
18. Leng L, et al. (2011) A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol 186:527-538.
19. Lubetsky JB, et al. (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277:24976-24982. (Pubitemid 34951799)
20. Suzuki M, et al. (1996) Crystal structure of the macrophage migration inhibitory factor from rat liver. Nat Struct Biol 3:259-266. (Pubitemid 26081709)
21. Cvetkovic I, et al. (2005) Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 146:2942-2951. (Pubitemid 41002801)
22. Al-Abed Y, VanPatten S (2011) MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem 3:45-63.
23. Sugimoto H, et al. (1995) Crystallization of rat liver macrophage migration inhibitory factor for MAD analysis. J Struct Biol 115:331-334. (Pubitemid 26041559)
24. Bendrat K, et al. (1997) Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 36:15356-15362. (Pubitemid 27528002)
25. Dios A, et al. (2002) Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 45:2410-2416. (Pubitemid 34595211)
26. Senter PD, et al. (2002) Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 99:144-149. (Pubitemid 34060331)
27. Crichlow GV, et al. (2007) Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J Biol Chem 282:23089-23095. (Pubitemid 47311928)
28. Wang F, et al. (2010) Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats. Pain 148:275-283.
29. Hou XQ, et al. (2009) Role of macrophage migration inhibitory factor in influenza H5N1 virus pneumonia. Acta Virol 53:225-231.
30. Piette C, et al. (2009) The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors. J Biol Chem 284:32483-32492.
31. He XX, et al. (2009) Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 15:1-10.
32. Saeed RW, et al. (2004) Ethanol blocks leukocyte recruitment and endothelial cell activation in vivo and in vitro. J Immunol 173:6376-6383. (Pubitemid 39487797)
33. Moley JF, Ohkawa M, Chaudry IH, Clemens MG, Baue AE (1984) Hypothyroidism abolishes the hyperdynamic phase and increases susceptibility to sepsis. J Surg Res 36:265-273. (Pubitemid 14162498)